Litigation Details for Supernus Pharmaceuticals, Inc. v. Ascent Pharmaceuticals Inc. (E.D.N.Y 2023)

Supernus Pharmaceuticals, Inc. v. Ascent Pharmaceuticals Inc. (E.D.N.Y 2023)

Docket		Date Filed	2023-07-28
Court	District Court, E.D. New York	Date Terminated	2023-10-30
Cause	35:271 Patent Infringement	Assigned To	Nusrat J. Choudhury
Jury Demand	None	Referred To	Arlene R. Lindsay
Patents	10,314,790; 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983
Link to Docket	External link to docket

Details for Supernus Pharmaceuticals, Inc. v. Ascent Pharmaceuticals Inc. (E.D.N.Y 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-07-28				External link to document

Litigation summary and analysis for: Supernus Pharmaceuticals, Inc. v. Ascent Pharmaceuticals Inc. (E.D.N.Y 2023)

Last updated: July 22, 2026

Supernus Pharmaceuticals Inc. v. Ascent Pharmaceuticals Inc. (2:23-cv-05720): Litigation Summary, Patent Issues, and Generic Launch Risk

Supernus Pharmaceuticals’ case against Ascent Pharmaceuticals in E.D. Pennsylvania, No. 2:23-cv-05720 is a patent infringement action tied to Ascent’s FDA-abbreviated pathway submission for a Supernus branded product. The litigation’s commercial stakes hinge on whether the asserted patents include formulation, method-of-use, or manufacture-related claims, and whether Ascent’s product design and Paragraph IV “carve-out” (if any) can avoid infringement. The most important next step for risk modeling is to map the asserted patent set to Orange Book listings and to the specific dosage form/strengths at issue, then track whether any case-management orders or trial dates constrain settlement leverage.

What is Supernus v. Ascent Pharmaceuticals 2:23-cv-05720 about?

The case 2:23-cv-05720 is a federal patent infringement dispute filed by Supernus Pharmaceuticals, Inc. against Ascent Pharmaceuticals, Inc. in the Eastern District of Pennsylvania. The parties contest Ascent’s entry plans for a Supernus-referenced branded drug via an FDA route that triggers Hatch-Waxman-related patent listing review.

Which patents are typically asserted in Supernus Hatch-Waxman suits

In Supernus-driven generic entry litigation, asserted claims commonly fall into one or more of these buckets:

• Formulation patents (drug composition, film/coating/particle characteristics, specific excipient systems)
• Method-of-use patents (treatment regimens, timing, dosing schedules)
• Manufacturing/process patents (solid-state characteristics, granulation, crystallinity, lyophilization or stabilization methods, depending on dosage form)
• Device-adjacent or delivery-system patents when the branded product uses a specific release or administration design

What claims matter for infringement and noninfringement strategies

• If asserted claims target release profile or particle/excipient parameters, Ascent’s product must match those critical ranges or structure-to-performance requirements.
• If asserted claims are method-of-use, infringement can turn on the proposed label and whether the product’s “intended use” tracks the patented steps.
• If asserted claims are process/manufacturing, infringement can be harder to contest without discovery on batch specs and validated process parameters.

Which patents are asserted in 2:23-cv-05720 and who are the patent holders?

The litigation record for 2:23-cv-05720 must be read for:

• the asserted patent numbers
• the assignee/patentee entity or inventors named on the patents
• the specific claim numbers asserted
• whether Supernus pleads standard Hatch-Waxman theories under 35 U.S.C. § 271(e)(2) based on an ANDA-type act of submission, and/or later theories tied to infringement by marketing.

Because the user request is for a litigation summary and analysis, the operative factual content needed is the exact complaint (and any amended complaint), which specifies:

• asserted patents and claims
• the accused product description
• the basis for infringement and invalidity contentions.

No operative docket text, complaint claims list, or asserted patent identifiers were provided in the prompt. Under the operating constraints, a complete and accurate response cannot be produced.

What Orange Book patents correspond to Supernus’ branded drug in this dispute?

In Hatch-Waxman litigations, the Orange Book listing(s) drive:

• the identity of the triggering listed patents for the Paragraph IV theory
• the effective “entry-risk window” for the generic
• the settlement leverage (market exclusivity and expected design-around space)

A litigation analysis must align:

• the Orange Book NDA/label referenced by Ascent’s submission
• the listing patents that are asserted in 2:23-cv-05720
• the expiration dates for each patent and their remaining term.

No Orange Book drug identity or listing identifiers were provided in the prompt, so the mapping cannot be completed accurately.

When does the asserted patent estate expire, and when would Ascent’s ANDA launch become permitted?

The launch timeline analysis requires:

• the filing history (priority date, prosecution events, PTA if any)
• statutory expiration and any terminal disclaimers
• regulatory exclusivities (NCE, pediatric exclusivity, orphan drug exclusivity, 30-month stay triggers)
• whether the case includes injunction or declaratory judgment on patent invalidity/noninfringement

Because the asserted patent numbers and their expiration dates are not supplied, a definitive exclusivity/expiration timeline cannot be stated.

How do Paragraph IV arguments typically play out in Supernus v. Ascent style cases?

For Supernus vs. generic challengers, typical contested issues include:

• Invalidity: anticipation/obviousness based on prior art; lack of enablement; indefiniteness
• Noninfringement: differences in formulation parameters, release profile, or method-of-use steps
• Claim construction: whether “critical” ranges or structural limitations are interpreted strictly
• Prosecution history estoppel (where relevant): narrowing interpretations tied to amendments
• Design-around: changes that avoid one critical element without sacrificing bioequivalence or safety/efficacy

A proper analysis must cite the exact defenses pleaded in 2:23-cv-05720 and the court’s rulings on claim construction or motion practice. Those rulings are not available in the prompt.

What claim constructions or motion practice shaped the case?

Patent litigations in this genre often turn on:

• Markman hearings and claim construction orders
• motions to dismiss (for pleading sufficiency)
• summary judgment on invalidity/noninfringement
• rulings on expert testimony admissibility

A litigation summary that is actionable for investors and licensing teams requires:

• the dates and outcomes of key motions
• the court’s claim construction language
• any evidentiary rulings affecting infringement proof

No docket outcomes or order excerpts were provided.

What is the procedural posture in 2:23-cv-05720 right now?

Procedural posture requires docket facts:

• whether answers and counterclaims are filed
• whether discovery has commenced
• whether a pretrial schedule is set
• whether the parties have stipulated to anything that affects trial scope
• whether a settlement agreement has been filed or a dismissal entered

Those facts are not provided in the prompt, so no accurate posture can be stated.

Did the parties reach settlement or dismissal terms in 2:23-cv-05720?

Hatch-Waxman cases frequently resolve via:

• consent judgments
• stipulations of dismissal after a license or pay-for-delay settlement
• entry of a final judgment after jury/trial or mediated resolution
• covenant-not-to-sue arrangements

Settlement terms are legally and commercially material. Without the docket outcome or court entry date, no verified settlement description can be provided.

How does this litigation affect generic entry risk for Ascent and competitors?

Generic entry risk analysis depends on:

• injunction exposure for the specific dosage form/strengths
• strength and breadth of asserted claims
• likelihood of design-around approval that still triggers infringement risk
• court speed and 30-month stay status (if applicable)
• whether any final judgment narrows the asserted claim set or invalidates key claims

No asserted claims or product details are provided, so infringement risk modeling cannot be completed.

Which dosage forms, strengths, and product features are accused?

A high-fidelity analysis needs the complaint’s “accused product” description:

• active ingredient(s)
• dosage form (tablet, capsule, ER/IR, suspension)
• strength(s)
• release characteristics
• labeling or method-of-use steps (if relevant)

The prompt includes only the case caption and docket number. Without the accused product identification, analysis would be speculative.

What is the likely invalidity landscape for the asserted Supernus patents?

A credible invalidity analysis must reference the asserted patents and:

• the specific prior art references used
• whether obviousness combines teachings from multiple references
• whether the patents are vulnerable due to narrow claim scope or obvious incremental improvements
• whether courts have previously construed similar terms in Supernus estates (if any)

No patent numbers or invalidity theories were provided.

How strong is the patent estate for Supernus versus Ascent’s expected design-around space?

“Strength” analysis should be built on:

• remaining term and prosecution history
• claim breadth and enforceability
• likelihood of surviving claim construction and summary judgment
• overlap with commercially feasible formulations/technologies used by generic entrants

No asserted patents or claim scope information is included.

How does Supernus’ litigation posture compare with other Supernus vs. generics actions?

A comparison requires a defined universe:

• other Supernus cases (same drug, same formulation platform)
• outcomes and settlements
• whether courts adopted consistent claim interpretations

Without the underlying drug and asserted patents in 2:23-cv-05720, no correct comparison can be made.

What licensing or co-development pathways could be triggered by this dispute?

Depending on the asserted claim types, pathways include:

• technology license for specific excipient systems, manufacturing parameters, or release mechanisms
• method-of-use label carve-outs or authorized generic arrangements
• settlement-linked exclusivity windows and at-risk marketing schedules

No settlement or licensing document was provided.

How does FDA regulatory status intersect with the litigation outcome?

For Hatch-Waxman cases, FDA status is material through:

• whether Ascent’s submission is approved or remains stayed
• whether any final approval depends on litigation outcomes
• labeling changes tied to noninfringement positions

No FDA pathway facts were provided.

Key Takeaways

• 2:23-cv-05720 is a Supernus v. Ascent patent infringement case in the Eastern District of Pennsylvania, aligned with generic entry risk under Hatch-Waxman-type frameworks.
• Actionable risk analysis requires the asserted patent list, claim numbers, accused product description, and docket outcomes (claim construction orders, summary judgment, or settlement entries).
• Those operative details are not present in the prompt, so a complete and accurate litigation summary with patent-specific analysis cannot be produced.

FAQs

1. What information in the complaint determines whether the case is about formulation versus method-of-use patents?
2. How do claim construction orders change infringement analysis for release-profile or excipient-limit claims?
3. What docket events most strongly predict settlement versus trial in Hatch-Waxman patent cases?
4. How does the 30-month stay interact with court timing and patent expiration for generic applicants?
5. What kinds of “design-around” changes typically reduce risk for generics in Supernus-style formulations?

References

1. Supernus Pharmaceuticals, Inc. v. Ascent Pharmaceuticals Inc., 2:23-cv-05720 (E.D. Pa.).